RE:RE:RE:RE:RE:RE:RE:RE:Napkin Mathhmmmmmm...again you just can't take a hint or direct statement that your banter is tiresome and repetitive. I have no reason or requirement to toss comments back and forth with you as it achieves nothing for me. You've said and done nothing that has earned you any credibility.
I call out management when I feel it's warranted. I'll also compliment them when something noteworthy is done. It's a dynamic world we live in and today's direction can be exactly the opposite tomorrow or the next day.
Here's what I know. Baxter has a deal with Spectral most of which is redacted. Baxter recently determined to make a direct investment into Spectral. Baxter also recently announced a reorganization with KidneyCo - a $5 billion spinoff - which prominently featured the EAA and PMX amongst just a few products. Launch is 12 to 18 months which is January 2024 to July 2024. In unrelated news, Spectral granted each of Seto and Kellum 2,250,000 PSU's each to get PMX FDA approved by June 30 2023 (2,250,000 PSU's earned each) or December 31, 2023 (1,500,000 PSU's earned each). Failing which their entitlement effectively vanishes. Big payday if they pass GO in time - defined as calendar year 2023. So far the 53 finished of the 150 trial total are exceeding expectations.
If Spectral isn't done getting PMX FDA approved by January 2024 I would think Baxter would have given themselves the option of taking it over at that time to feature it in the KidneyCo public company rollout. So Spectral has given management a huge personal incentive to get it successfully finished by the end of 2023. Failing which, based on logical speculation, Baxter would take over but likely at a lower price to Spectral. So while the delay is frustrating I have no doubt about the ultimate success of PMX.
Not trying to start a debate with you. Exactly the opposite would be my first choice. So as MM suggested lower your anxiety, make real contributions here or take up option 3 in the list.